Company
Servier
Servier has 36 drugs tracked on RxWires: 2 post-market, 7 in Phase 3, 1 in Phase 2/3, 13 in Phase 2, 6 in Phase 1/2, 7 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Gliclazide MR and Insulin Glargine Injection | Post-Market | Type 2 Diabetes |
| Indapamide SR 1.5mg; Perindopril 2-4mg | Post-Market | Hypertension |
| Futibatinib | Phase 3 | Biliary Tract Neoplasms |
| Futuximab/modotuximab | Phase 3 | Metastatic Colorectal Cancer |
| Ivosidenib 500mg Oral Tablet | Phase 3 | Acute Myeloid Leukemia (AML) |
| AG-120 | Phase 3 | Newly Diagnosed Acute Myeloid Leukemia (AML) |
| Trifluridine/Tipiracil | Phase 3 | Refractory Metastatic Colorectal Cancer |
| Gevokizumab | Phase 3 | Behcet's Uveitis |
| - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril. | Phase 3 | Heart Failure |
| Prednisone | Phase 2/3 | Acute Lymphoblastic Leukemia |
| lucitanib | Phase 2 | Breast Cancer |
| Onivyde | Phase 2 | Squamous Cell Carcinoma |
| Vorasidenib | Phase 2 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation |
| S47445 5mg | Phase 2 | Alzheimer's Disease |
| Agomelatine A | Phase 2 | Obsessive Compulsive Disorder |
| Trifluridine/tipiracil + bevacizumab | Phase 2 | Metastatic Colorectal Cancer |
| SHP674 | Phase 2 | Acute Lymphoblastic Leukemia |
| Nal-IRI | Phase 2 | PDAC - Pancreatic Ductal Adenocarcinoma |
| nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA) | Phase 2 | Pancreatic Cancer |
| Liposomal Irinotecan | Phase 2 | Esophageal Cancer |
| Ivosidenib + oral azacitidine | Phase 2 | Acute Myeloid Leukemia |
| Combination of Lonsurf® and Irinotecan | Phase 2 | Cholangiocarcinoma |
| Lonsurf | Phase 2 | Metastatic Colorectal Cancer |
| S241656 | Phase 1/2 | Acute Myeloid Leukemia |
| S243249 600mg | Phase 1/2 | Relapsed or Refractory Acute Leukemia |
| BN104 monotherapy | Phase 1/2 | ALL, Adult |
| Combination therapy (S81694 + paclitaxel) phase I | Phase 1/2 | Metastatic Breast Cancer |
| S095018 | Phase 1/2 | Non-small Cell Lung Cancer (NSCLC) |
| S095035 | Phase 1/2 | MTAP-deleted Solid Tumors |
| Other | Phase 1 | Type 2 Diabetes Mellitus |
| S64315 once a week | Phase 1 | Acute Myeloid Leukaemia (AML) |
| S 55746 | Phase 1 | Chronic Lymphocytic Leukaemia (CLL) |
| AG-270 | Phase 1 | Advanced Solid Tumors |
| Ivabradine and placebo | Phase 1 | Healthy Individual |
| UCART19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia |
| S 95010 | Phase 1 | Cardiovascular Diseases |
Latest
No recent events.
Follow Servier on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.